ESC 365 - Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

ESC Premium Access

Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

Session: Poster Session 7 - Chronic heart failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor T. Ichiki (Rochester, US)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Tomoko Ichiki

Mayo Clinic, Rochester (United States of America)

0 follower

8 more presentations in this session

Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Identification of patients eligible to start sacubitril valsartan in a stable heart failure population

Speaker: Doctor S. Aktaa (Leeds, GB)

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Speaker: Doctor P. Pellicori (Glasgow, GB)

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Speaker: Doctor M. Senni (Bergamo, IT)

Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction

Speaker: Doctor M. Li (Osaka, JP)

Access the full session

Poster Session 7 - Chronic heart failure – Treatment

Speakers: Doctor T. Ichiki, Doctor I. Hernandez Gonzalez, Doctor S. Aktaa, Doctor P. Pellicori, Doctor M. Senni...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources